[Changes of serum 25-hydroxyvitamin D3 and interleukin-6 after treatment with intravenous immunoglobulins in children with Kawasaki disease]

Nan Fang Yi Ke Da Xue Xue Bao. 2014 Jul;34(8):1230-2.
[Article in Chinese]

Abstract

Objective: To explore the changes of serum 25-hydroxyvitamin D3 [25-(OH)D3] and interleukin-6 (IL-6) in children with Kawasaki disease (KD) after treatment with intravenous immunoglobulins (IVIG) and analyze their clinical implications.

Methods: Thirty-five children with KD (26 boys and 9 girls) were examined for serum 25-(OH)D3 and IL-6 levels before and after IVIG treatment using enzyme linked immunosorbent assay (ELISA), with 25 febrile children with respiratory tract infections and 25 healthy children as controls.

Results: Serum 25-(OH)D3 levels were significantly higher in healthy children than in febrile children (P=0.025), and was even higher in children with KD before IVIG treatment (P=0.023). Serum IL-6 levels were similar between healthy and febrile children (P=0.4), but significantly elevated in KD children (P=0.000). Serum 25-(OH)D3 level was positive correlated with serum IL-6 level in KD children before treatment (r=0.9, P=0.000). In KD children after IVIG treatment, serum 25-(OH)D3 level was significantly increased (P=0.012) and serum IL-6 levels slightly decreased (P=0.325) without showing any correlations (r=0.18, P=0.4).

Conclusion: Serum 25-(OH)D3 level is positively correlated with serum IL-6 level in KD children before IVIG treatment but not after the treatment,. 25(OH)D3 may participate in the pathogenesis of KD and potentially serves as the therapeutic target for KD.

MeSH terms

  • Calcifediol / blood*
  • Case-Control Studies
  • Child
  • Female
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Interleukin-6 / blood*
  • Male
  • Mucocutaneous Lymph Node Syndrome / blood
  • Mucocutaneous Lymph Node Syndrome / drug therapy*

Substances

  • IL6 protein, human
  • Immunoglobulins, Intravenous
  • Interleukin-6
  • Calcifediol